Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rivastigmine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Rivastigmine. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-003385-24 Sponsor Protocol Number: 2815 Start Date*: 2016-09-28
    Sponsor Name:GGZ inGeest, parner VUmc
    Full Title: The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial
    Medical condition: Interictal delirium during electric convulsive therapy- course
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005633-33 Sponsor Protocol Number: 202000842 Start Date*: 2021-06-02
    Sponsor Name:University Medical Center Groningen
    Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
    Medical condition: A depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006166-42 Sponsor Protocol Number: RIVA Start Date*: 2007-07-17
    Sponsor Name:University of Tuebingen
    Full Title: Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -
    Medical condition: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and don...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000507-17 Sponsor Protocol Number: SC1-04 Start Date*: 2004-06-10
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect
    Medical condition: Improvement of unilateral spatial neglect and functional status in right brain damaged patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003219-23 Sponsor Protocol Number: 2844 Start Date*: 2019-06-28
    Sponsor Name:University of Bristol
    Full Title: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
    Medical condition: This trial will investigate the effectiveness of Rivastigmine on prevention of falls in patients with Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003053-25 Sponsor Protocol Number: 1466 Start Date*: 2012-06-18
    Sponsor Name:Research and Enterprise Department
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004435-30 Sponsor Protocol Number: SC06-02 Start Date*: 2006-10-31
    Sponsor Name:FONDAZIONE SANTA LUCIA
    Full Title: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients.
    Medical condition: Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057668 Cognitive disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001383-46 Sponsor Protocol Number: Sweet 0406 Start Date*: 2004-10-25
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: Swdeish Exelon Titration study
    Medical condition: Patients with possible or probable Alzheimer disease (AD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008896-32 Sponsor Protocol Number: MACS(Uni-Koeln-1260) Start Date*: 2010-12-22
    Sponsor Name:University of Cologne
    Full Title: Memory, Ageing, and the Cholinergic System a combined fMRI and PET study
    Medical condition: Patients with mild cognitive impairment (MCI) (50-80 years), who are at greater risk of developing alzheimer's dementia will be recruited in the present study and will be compared to an age-matched...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000569-61 Sponsor Protocol Number: CHUBX2016/27 Start Date*: 2021-12-20
    Sponsor Name:CHU de Bordeaux
    Full Title: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial
    Medical condition: Alzheimer disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005300-41 Sponsor Protocol Number: IC-DEL Start Date*: 2008-05-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Rivastigmine for delirium in Intensive Care patients, a double-blind, randomised, placebo-controlled, multi-center add-on trial
    Medical condition: Delirium
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012218 Delirium LLT
    9.1 10012220 Delirium due to a general medical condition LLT
    9.1 10012226 Delirium, cause unknown LLT
    9.1 10013758 Drug-induced delirium LLT
    9.1 10012218 Delirium PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003965-42 Sponsor Protocol Number: 002 Start Date*: 2007-12-04
    Sponsor Name:University Medical Centre Utrecht
    Full Title: Methylphenidate, rivastigmine or haloperidol in hypoactive delirious intensive care patients: a single centre, randomized, mono-blind pilot trial
    Medical condition: Hypoactive delirious ICU-patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012218 Delirium LLT
    9.1 10012218 Delirium PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000350-31 Sponsor Protocol Number: CENA713B2315 Start Date*: 2008-01-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon® capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with m...
    Medical condition: Mild to moderately severe dementia associated with Parkinson’s disease (PDD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012284 Dementia due to Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007015-32 Sponsor Protocol Number: CENA713DDE18 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with mul...
    Medical condition: cognitive impairment in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005472-27 Sponsor Protocol Number: 70639 Start Date*: 2009-03-30
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen Polymorphismen
    Medical condition: Anhand der vorliegenden Studie soll untersucht werden, ob genetische Polymorphismen im CYP2D6-, im MDR1- oder im ACHE Gen mit sub- bzw. supratherapeutischen Wirkstoffspiegeln im Plasma, mit relevan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012071-10 Sponsor Protocol Number: 268/09 Start Date*: 2009-06-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study’
    Medical condition: PARKINSONISM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    9.1 10034005 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001383-70 Sponsor Protocol Number: CENA713DDE15 Start Date*: 2007-09-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 24 week, multicenter, open evaluation of the clinical effectiveness of the once-daily 10 cm2 Exelon® patch formulation in patients with probable Alzheimer’s disease (MMSE10-26)
    Medical condition: probable Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015632-15 Sponsor Protocol Number: P071244 Start Date*: 2010-01-22
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Essai en double aveugle contre placebo d'un traitement par inhibiteur de l'acétyl cholinesterase sur l'évolution d'un syndrome confusionnel chez les plus de 75 ans et évolution vers un syndrome dém...
    Medical condition: Syndrome confusionnel chez les personnes âgées de plus de 75 ans
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010304 Syndrome Confusionnel PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003405-27 Sponsor Protocol Number: CENA 713D FR08 Start Date*: 2007-09-10
    Sponsor Name:NOVARTIS PHARMA SAS
    Full Title: Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26)
    Medical condition: Maladie d'Alzheimer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 20:11:38 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA